Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.

Literature DB >> 27215781

Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.

Paula Morales¹, Laura Hernandez-Folgado¹, Pilar Goya¹, Nadine Jagerovic¹.

Abstract

INTRODUCTION: Modulation of the CB2 receptor is an interesting approach for pain and inflammation, arthritis, addictions, neuroprotection, and cancer, among other possible therapeutic applications, and is devoid of central side effects. AREAS COVERED: This review highlights the novel scaffolds for CB2 ligands and the diverse therapeutic applications for CB2 modulators disclosed in patents published since 2012. EXPERT OPINION: Structural diversity of CB2 modulator scaffolds characterized the patent literature. Several CB2 agonists reached clinical Phase II for pain management and inflammation. Other therapeutic applications need to be explored such as neuroprotection and/or neurodegeneration.

Entities: Disease Gene

Keywords: Cannabinoid receptor 2; HIV; cancer; endometriosis; inflammation; organ transplant; osteoarthritis; pain

Mesh：

Substances：

Year: 2016 PMID： 27215781 DOI： 10.1080/13543776.2016.1193157

Source DB: PubMed Journal: Expert Opin Ther Pat ISSN： 1354-3776 Impact factor: 6.674

Keyword Cloud
Cited

18 in total

Review 1. An overview of the cannabinoid type 2 receptor system and its therapeutic potential.

Authors: Bihua Bie; Jiang Wu; Joseph F Foss; Mohamed Naguib
Journal: Curr Opin Anaesthesiol Date: 2018-08 Impact factor: 2.706

2. Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities.

Authors: Alessandra Bisi; Alì Mokhtar Mahmoud; Marco Allará; Marina Naldi; Federica Belluti; Silvia Gobbi; Alessia Ligresti; Angela Rampa
Journal: ACS Med Chem Lett Date: 2019-02-26 Impact factor: 4.345

Review 3. New approaches and challenges to targeting the endocannabinoid system.

Authors: Vincenzo Di Marzo
Journal: Nat Rev Drug Discov Date: 2018-08-17 Impact factor: 84.694

4. Discovery of APD371: Identification of a Highly Potent and Selective CB₂ Agonist for the Treatment of Chronic Pain.

Authors: Sangdon Han; Lars Thoresen; Jae-Kyu Jung; Xiuwen Zhu; Jayant Thatte; Michelle Solomon; Ibragim Gaidarov; David J Unett; Woo Hyun Yoon; Jeremy Barden; Abu Sadeque; Amin Usmani; Chuan Chen; Graeme Semple; Andrew J Grottick; Hussein Al-Shamma; Ronald Christopher; Robert M Jones
Journal: ACS Med Chem Lett Date: 2017-11-30 Impact factor: 4.345

5. Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands.

Authors: Rareş-Petru Moldovan; Kristin Hausmann; Winnie Deuther-Conrad; Peter Brust
Journal: ACS Med Chem Lett Date: 2017-04-28 Impact factor: 4.345

6. Chronic pain patients' perspectives of medical cannabis.

Authors: Brian J Piper; Monica L Beals; Alexander T Abess; Stephanie D Nichols; Maurice W Martin; Catherine M Cobb; Rebecca M DeKeuster
Journal: Pain Date: 2017-07 Impact factor: 6.961

7. Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.

Authors: Jiaojiao Li; Jing Ji; Ruibo Xu; Zhengfu Li
Journal: Medchemcomm Date: 2019-09-17 Impact factor: 3.597

Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.

Review 1. An overview of the cannabinoid type 2 receptor system and its therapeutic potential.

2. Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities.

Review 3. New approaches and challenges to targeting the endocannabinoid system.

4. Discovery of APD371: Identification of a Highly Potent and Selective CB₂ Agonist for the Treatment of Chronic Pain.

5. Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands.

6. Chronic pain patients' perspectives of medical cannabis.

7. Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.

Review 8. The Clinical Significance of Endocannabinoids in Endometriosis Pain Management.

9. Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines.

Review 10. Novel approaches and current challenges with targeting the endocannabinoid system.

Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.

Review 1. An overview of the cannabinoid type 2 receptor system and its therapeutic potential.

2. Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities.

Review 3. New approaches and challenges to targeting the endocannabinoid system.

4. Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain.

5. Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands.

6. Chronic pain patients' perspectives of medical cannabis.

7. Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.

Review 8. The Clinical Significance of Endocannabinoids in Endometriosis Pain Management.

9. Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines.

Review 10. Novel approaches and current challenges with targeting the endocannabinoid system.

4. Discovery of APD371: Identification of a Highly Potent and Selective CB₂ Agonist for the Treatment of Chronic Pain.